Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
LETTER TO THE EDITOR F.R. Ali, J.T. Lear, Corresponding Author john.lear@nca.nhs.uk Mid Cheshire NHS Foundation Trust, Macclesfield, UK Dermatology Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Stott Lane, Manchester, M6 8HD UK Correspondence Dr J. T.
Summary Background Basal cell carcinomas (BCC s) exhibit aberrant activation of the hedgehog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC (laBCC ) and metastatic BCC (mBCC ) based on primary results of the BOLT study [Basal Cell Carcinoma Outcomes with LDE 225 (sonidegib) Treatment]. Objectives This is the final 42‐month analysis of the BOLT study, evaluating the efficacy and safety of sonidegib.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
